Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

被引：83
作者：
Nolan, L. [1 ]
Johnson, P. W. M. [1 ]
Ganesan, A. [2 ]
Packham, G. [1 ]
Crabb, S. J. [1 ]
机构：
[1] Univ Southampton, Southampton Gen Hosp, Canc Res UK Clin Ctr, Sch Med, Southampton SO16 6YD, Hants, England
[2] Univ Southampton, Southampton Gen Hosp, Sch Chem, Southampton SO16 6YD, Hants, England
来源：
BRITISH JOURNAL OF CANCER | 2008年 / 99卷 / 05期
关键词：
histone deacetylase; inhibitor; combination therapy;
D O I：
10.1038/sj.bjc.6604557
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these interactions.
引用
收藏
页码：689 / 694
页数：6
相关论文
共 34 条
[1]   Acute myeloid leukemia: Therapeutic impact of epigenetic drugs [J].
Altucci, L ;
Clarke, N ;
Nebbioso, A ;
Scognamiglio, A ;
Gronemeyer, H .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (09) :1752-1762
[2]   Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2 [J].
Bali, P ;
Pranpat, M ;
Swaby, R ;
Fiskus, W ;
Yamaguchi, H ;
Balasis, M ;
Rocha, K ;
Wang, HG ;
Richon, V ;
Bhalla, K .
CLINICAL CANCER RESEARCH, 2005, 11 (17) :6382-6389
[3]   It's about time: Scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells [J].
Bevins, RL ;
Zimmer, SG .
CANCER RESEARCH, 2005, 65 (15) :6957-6966
[4]   Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia [J].
Bug, G ;
Ritter, M ;
Wassmann, B ;
Schoch, C ;
Heinzel, T ;
Schwarz, K ;
Romanski, A ;
Kramer, OH ;
Kampfmann, M ;
Hoelzer, D ;
Neubauer, A ;
Ruthardt, M ;
Ottmann, OG .
CANCER, 2005, 104 (12) :2717-2725
[5]   Regulation of distinct biological activities of the NF-κB transcription factor complex by acetylation [J].
Chen, LF ;
Greene, WC .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2003, 81 (09) :549-557
[6]  
Crabb SJ, 2007, ADV BREAST CANC, V4, P40
[7]   RETRACTED: Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve mcl-1 and p21CIP1 down-regulation(Retracted article. See vol.22, pg.4959,2016) [J].
Dasmahapatra, Girija ;
Yerram, Nitin ;
Dai, Yun ;
Dent, Paul ;
Grant, Steven .
CLINICAL CANCER RESEARCH, 2007, 13 (14) :4280-4290
[8]   Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells [J].
Dowdy, Sean C. ;
Jiang, Shujuan ;
Zhou, X. Clare ;
Hou, Xiaonan ;
Jin, Fan ;
Podratz, Karl C. ;
Jiang, Shi-Wen .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2767-2776
[9]  
Fuino L, 2003, MOL CANCER THER, V2, P971
[10]  
Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217
1234